581 related articles for article (PubMed ID: 19068246)
1. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.
Katz G; Arad M; Eldar M
Curr Probl Cardiol; 2009 Jan; 34(1):9-43. PubMed ID: 19068246
[TBL] [Abstract][Full Text] [Related]
2. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights.
Kontula K; Laitinen PJ; Lehtonen A; Toivonen L; Viitasalo M; Swan H
Cardiovasc Res; 2005 Aug; 67(3):379-87. PubMed ID: 15913575
[TBL] [Abstract][Full Text] [Related]
3. Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia.
Mohamed U; Napolitano C; Priori SG
J Cardiovasc Electrophysiol; 2007 Jul; 18(7):791-7. PubMed ID: 17578347
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetics of exercise-induced polymorphic ventricular tachycardia: identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms.
Laitinen PJ; Swan H; Kontula K
Eur J Hum Genet; 2003 Nov; 11(11):888-91. PubMed ID: 14571276
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of abnormal calcium homeostasis in mutations responsible for catecholaminergic polymorphic ventricular tachycardia.
Iyer V; Hajjar RJ; Armoundas AA
Circ Res; 2007 Feb; 100(2):e22-31. PubMed ID: 17234962
[TBL] [Abstract][Full Text] [Related]
6. Catecholaminergic polymorphic ventricular tachycardia.
Liu N; Colombi B; Raytcheva-Buono EV; Bloise R; Priori SG
Herz; 2007 May; 32(3):212-7. PubMed ID: 17497254
[TBL] [Abstract][Full Text] [Related]
7. A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations.
de la Fuente S; Van Langen IM; Postma AV; Bikker H; Meijer A
Pacing Clin Electrophysiol; 2008 Jul; 31(7):916-9. PubMed ID: 18684293
[TBL] [Abstract][Full Text] [Related]
8. Genetic characterization of familial CPVT after 30 years.
Beery TA; Shah MJ; Benson DW
Biol Res Nurs; 2009 Jul; 11(1):66-72. PubMed ID: 19398417
[TBL] [Abstract][Full Text] [Related]
9. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia.
Marks AR; Priori S; Memmi M; Kontula K; Laitinen PJ
J Cell Physiol; 2002 Jan; 190(1):1-6. PubMed ID: 11807805
[TBL] [Abstract][Full Text] [Related]
11. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients.
Postma AV; Denjoy I; Kamblock J; Alders M; Lupoglazoff JM; Vaksmann G; Dubosq-Bidot L; Sebillon P; Mannens MM; Guicheney P; Wilde AA
J Med Genet; 2005 Nov; 42(11):863-70. PubMed ID: 16272262
[TBL] [Abstract][Full Text] [Related]
12. Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death.
Terentyev D; Nori A; Santoro M; Viatchenko-Karpinski S; Kubalova Z; Gyorke I; Terentyeva R; Vedamoorthyrao S; Blom NA; Valle G; Napolitano C; Williams SC; Volpe P; Priori SG; Gyorke S
Circ Res; 2006 May; 98(9):1151-8. PubMed ID: 16601229
[TBL] [Abstract][Full Text] [Related]
13. [Genetic of catecholaminergic polymorphic ventricular tachycardia: basic concepts].
Medeiros-Domingo A
Arch Cardiol Mex; 2009 Dec; 79 Suppl 2():13-7. PubMed ID: 20361477
[TBL] [Abstract][Full Text] [Related]
14. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
[TBL] [Abstract][Full Text] [Related]
15. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations.
Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O
J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920
[TBL] [Abstract][Full Text] [Related]
16. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.
Song L; Alcalai R; Arad M; Wolf CM; Toka O; Conner DA; Berul CI; Eldar M; Seidman CE; Seidman JG
J Clin Invest; 2007 Jul; 117(7):1814-23. PubMed ID: 17607358
[TBL] [Abstract][Full Text] [Related]
17. Catecholaminergic polymorphic ventricular tachycardia.
Liu N; Ruan Y; Priori SG
Prog Cardiovasc Dis; 2008; 51(1):23-30. PubMed ID: 18634915
[TBL] [Abstract][Full Text] [Related]
18. Catecholaminergic polymorphic ventricular tachycardia in a child: a case report.
Garabedian L; Verryckt A; Panzer J; De Wolf D
Acta Paediatr; 2008 Jan; 97(1):127-9. PubMed ID: 18052993
[TBL] [Abstract][Full Text] [Related]
19. The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling.
Kirchhefer U; Wehrmeister D; Postma AV; Pohlentz G; Mormann M; Kucerova D; Müller FU; Schmitz W; Schulze-Bahr E; Wilde AA; Neumann J
J Mol Cell Cardiol; 2010 Jul; 49(1):95-105. PubMed ID: 20302875
[TBL] [Abstract][Full Text] [Related]
20. Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves.
Paavola J; Viitasalo M; Laitinen-Forsblom PJ; Pasternack M; Swan H; Tikkanen I; Toivonen L; Kontula K; Laine M
Eur Heart J; 2007 May; 28(9):1135-42. PubMed ID: 17347175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
